Nasdaq Bear Market: 3 Remarkable Growth Stocks Down 86% to 95% That Can Double Your Money in 2023The Motley Fool • 12/13/22
Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in AdolescentsPRNewsWire • 12/07/22
Is Novavax Stock A Buy On Its Massive Sales Beat Despite Unexpected Losses?Investors Business Daily • 12/06/22
3 Supercharged Growth Stocks With 393% to 1,153% Upside in 2023, According to Wall StreetThe Motley Fool • 12/06/22
Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap ConferencePRNewsWire • 12/02/22
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in AdultsPRNewsWire • 11/29/22
Nasdaq Bear Market: 3 Remarkable Growth Stocks Down Over 90% That Can Double Your Money by 2025The Motley Fool • 11/22/22
Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in AdultsPRNewsWire • 11/18/22
Nasdaq Bear Market: 3 Phenomenal Bargains That Can Double Your Money by 2027The Motley Fool • 11/10/22
Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in AdultsPRNewsWire • 11/09/22